​

Insmed (INSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INSM Stock Forecast

Insmed (INSM) stock forecast, based on 35 Wall Street analysts, predicts a 12-month average price target of $199.45, with a high of $231.00 and a low of $161.00. This represents a 86.54% increase from the last price of $106.92.

- $50 $100 $150 $200 $250 High: $231 Avg: $199.45 Low: $161 Last Closed Price: $106.92

INSM Stock Rating

Insmed stock's rating consensus is Buy, based on 35 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 33 Buy (94.29%), 1 Hold (2.86%), 1 Sell (2.86%), and 0 Strong Sell (0.00%).

Buy
Total 35 1 1 33 Strong Sell Sell Hold Buy Strong Buy

INSM Price Target Upside V Benchmarks

TypeNameUpside
StockInsmed86.54%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3746
Avg Price Target$191.00$190.86$207.46
Last Closing Price$106.92$106.92$106.92
Upside/Downside78.64%78.51%94.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26517---22
Jun, 26517---22
May, 26417---21
Apr, 26317---20
Mar, 262171--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 20, 2026Conor MacKayBMO Capital$192.00$107.0279.41%79.57%
Jul 20, 2026Andrew FeinH.C. Wainwright$220.00$108.32103.10%105.76%
Jul 15, 2026Wells Fargo$161.00$110.1146.22%50.58%
Jun 16, 2026Graig SuvannavejhMizuho Securities$192.00$97.4697.00%79.57%
May 13, 2026Truist Financial$185.00$116.5658.72%73.03%
May 08, 2026Wells Fargo$160.00$105.0052.38%49.64%
May 08, 2026Vamil DivanGuggenheim$226.00$105.00115.24%111.37%
Apr 16, 2026Guggenheim$230.00$146.7456.74%115.11%
Apr 14, 2026RBC Capital$216.00$151.1442.91%102.02%
Apr 10, 2026Raymond James$200.00$155.8028.37%87.06%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 20, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2026Wells FargoOverweightOverweighthold
Jun 10, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 08, 2026Roth CapitalBuyBuyhold
Jun 05, 2026RBC CapitalOutperformOutperformhold
May 08, 2026H.C. WainwrightBuyBuyhold
May 08, 2026GuggenheimBuyBuyhold
Apr 16, 2026GuggenheimBuyBuyhold
Apr 14, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.88$-3.91$-5.34$-5.57$-6.42---
Avg Forecast$-3.82$-3.72$-5.21$-5.36$-4.35$-2.65$0.86$4.09
High Forecast$-3.26$-3.04$-5.10$-5.21$-3.10$-0.94$4.06$5.65
Low Forecast$-4.43$-4.82$-5.34$-5.57$-5.38$-4.65$-0.81$3.23
Surprise %1.57%5.11%2.50%3.92%47.59%---

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$188.46M$245.36M$305.21M$363.71M$606.42M---
Avg Forecast$179.85M$247.85M$303.42M$357.89M$506.74M$1.03B$1.94B$2.87B
High Forecast$202.16M$304.60M$392.20M$364.25M$660.57M$1.04B$2.51B$3.71B
Low Forecast$159.62M$213.35M$303.41M$351.53M$414.94M$1.02B$1.63B$2.40B
Surprise %4.79%-1.00%0.59%1.62%19.67%---

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-434.65M$-481.53M$-749.57M$-913.77M$-1.28B---
Avg Forecast$-400.47M$-434.01M$-749.57M$-757.05M$-595.36M$-478.57M$157.64M$574.37M
High Forecast$-320.37M$-347.20M$-599.65M$-732.14M$-435.02M$-131.70M$570.16M$792.86M
Low Forecast$-480.56M$-520.81M$-899.48M$-781.97M$-755.70M$-652.68M$-113.75M$453.50M
Surprise %8.54%10.95%-20.70%114.45%---

INSM Forecast FAQ

Is Insmed stock a buy?

Insmed stock has a consensus rating of Buy, based on 35 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 33 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Insmed is a favorable investment for most analysts.

What is Insmed's price target?

Insmed's price target, set by 35 Wall Street analysts, averages $199.45 over the next 12 months. The price target range spans from $161 at the low end to $231 at the high end, suggesting a potential 86.54% change from the previous closing price of $106.92.

How does Insmed stock forecast compare to its benchmarks?

Insmed's stock forecast shows a 86.54% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Insmed over the past three months?

  • July 2026: 22.73% Strong Buy, 77.27% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 22.73% Strong Buy, 77.27% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 19.05% Strong Buy, 80.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Insmed’s EPS forecast?

Insmed's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.65, marking a -58.72% decrease from the reported $-6.42 in 2025. Estimates for the following years are $0.86 in 2027, and $4.09 in 2028.

What is Insmed’s revenue forecast?

Insmed's average annual revenue forecast for its fiscal year ending in December 2026 is $1.03B, reflecting a 70.20% increase from the reported $606.42M in 2025. The forecast for 2027 is $1.94B, and $2.87B for 2028.

What is Insmed’s net income forecast?

Insmed's net income forecast for the fiscal year ending in December 2026 stands at $-479M, representing a -62.52% decrease from the reported $-1.277B in 2025. Projections indicate $157.64M in 2027, and $574.37M in 2028.